Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Orogen Royalties Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2020-01-01

Employees: 10K

Market Cap: -

Website: http://www.organon.com

Introduction: Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Clinical Trials

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: asenapine
Drug: olanzapine

First Posted Date: 2005-09-21

Last Posted Date: 2024-08-15

Lead Sponsor: Organon and Co

Target Recruit Count: 481

Registration Number: NCT00212836

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)

Phase 3

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: asenapine
Drug: olanzapine

First Posted Date: 2005-09-21

Last Posted Date: 2022-02-16

Lead Sponsor: Organon and Co

Target Recruit Count: 440

Registration Number: NCT00212771

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)

Phase 3

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: asenapine
Drug: olanzapine

First Posted Date: 2005-09-21

Last Posted Date: 2024-08-15

Lead Sponsor: Organon and Co

Target Recruit Count: 1225

Registration Number: NCT00212784

IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

Phase 3

Completed

Conditions: Hypercholesterolemia
Myocardial Infarction

Interventions: Drug: ezetimibe/simvastatin
Drug: simvastatin
Drug: Placebo for simvastatin 40 mg
Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination

First Posted Date: 2005-09-20

Last Posted Date: 2024-06-18

Lead Sponsor: Organon and Co

Target Recruit Count: 18144

Registration Number: NCT00202878

Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)

Phase 4

Completed

Conditions: Hypercholesterolemia
Coronary Heart Disease

Interventions: Drug: placebo
Drug: ezetimibe

First Posted Date: 2005-09-20

Last Posted Date: 2022-02-16

Lead Sponsor: Organon and Co

Target Recruit Count: 81

Registration Number: NCT00202904

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: asenapine
Drug: olanzapine

First Posted Date: 2005-09-15

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 196

Registration Number: NCT00174265

Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)

Phase 4

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: ezetimibe (+) simvastatin
Drug: atorvastatin

First Posted Date: 2005-09-14

Last Posted Date: 2024-05-22

Lead Sponsor: Organon and Co

Target Recruit Count: 203

Registration Number: NCT00166504

EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)

Phase 4

Completed

Conditions: Atherosclerosis

Interventions: Drug: simvastatin
Drug: ezetimibe (+) simvastatin
Drug: atorvastatin

First Posted Date: 2005-09-14

Last Posted Date: 2024-08-15

Lead Sponsor: Organon and Co

Target Recruit Count: 367

Registration Number: NCT00166530

Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)

Phase 4

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: simvastatin (+) ezetimibe
Drug: atorvastatin

First Posted Date: 2005-09-12

Last Posted Date: 2024-06-07

Lead Sponsor: Organon and Co

Target Recruit Count: 190

Registration Number: NCT00157924

Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Other: Placebo arm
Drug: Asenapine
Drug: Haloperidol

First Posted Date: 2005-09-12

Last Posted Date: 2024-08-15

Lead Sponsor: Organon and Co

Target Recruit Count: 460

Registration Number: NCT00156104

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy